Onyx Scientific is set to increase the size of its U.K.-based site by more than 30% as it enjoys the spoils of a lucrative 2015.

Contract drug developer AMRI bolstered its client roster with three new agreements making use of its R&D, manufacturing and marketing divisions.

Chinese contract drug developer ShangPharma is planning to invest $60 million to build a biologics research and manufacturing outpost near its home base in…

Covance, now a division of LabCorp, is planning to build a second manufacturing-enabled pharmacy adjacent to one of its clinical research sites, allowing the…

Swedish contract drugmaker Recipharm signed a deal with neighboring LobSor Pharmaceuticals to manufacture the company's new treatment for Parkinson…

China's Shenzhen Hepalink Pharmaceutical signed a deal to acquire contract drugmaker Cytovance Biologics for $205.7 million in cash, buying into the U.…

Contract drugmaker Patheon inked a deal to manufacture Flexion Therapeutics' top prospect as it moves through clinical development.

Contract drug developer Avista Pharma Solutions bought the manufacturing, development and animal health services business of rival Scynexis, building up its…

French contract drugmaker Novasep is investing €10 million ($11 million) to build an antibody-drug conjugate facility at its Le Mans outpost.

Manufacturing